A Study To Test An Anti-Rejection Therapy After Kidney Transplantation

Stopped early · Phase 3

Conditions studied: Kidney Transplantation

In brief

Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective. Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.

Key facts

Study ID

NCT00000936

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

292

Starts

1999-11-01

Expected to finish

2004-03-01

Last updated by the study team

2017-01-11

Who can join

Age: any, up to 20. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children and young adults may be eligible for this study if they:
• Are not yet 21 years of age.
• Are receiving their first or second transplant.
• Are not pregnant.
• Agree to practice sexual abstinence or agree to use an effective
• method of birth control/contraception during the study and
• for 1 year after.

You may not qualify if…

• Children and young adults will not be eligible for this study if they:
• Are recipients of multiple organs other than kidneys.
• Are recipients of three or more transplants.
• Are HIV positive.
• Are Hepatitis B surface antigen positive.

Where it is running

• Ilene Blechman-Krom — Rockville, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.